Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

Shots: Kodiak has reported the P-III (DAYBREAK) trial data assessing Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in parallel vs aflibercept in pts with wet age-related macular degeneration (wAMD) Zenkuda met its 1EP, showing meaningful vision gains & rapid, sustained retinal drying, with 54% of pts achieving 6mos. durability at Yr. 1. tabirafusp-ted also met its vision…

ByRidhi RastogiSeptember 29, 2026

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Contact US

FOLLOW US